TMO · 10-Q · 2026Q3 · Full report
Liquidity and Debt Position
THERMO FISHER SCIENTIFIC INC. · 2026-10-30 · Importance 42 · Surprise 14 · From source text
At September 26, 2026, Thermo Fisher held $5.461 billion of cash and cash equivalents, down from $9.852 billion at December 31, 2025, and reported total debt of $41.370 billion, up from $39.384 billion. Short-term obligations and current maturities totaled $2.26 billion, while the company had no borrowings outstanding under its $5.00 billion unsecured revolving credit facility. Management stated that cash, operating cash flow, and available revolving-credit capacity were sufficient to meet cash requirements for at least the next 24 months. Approximately half of cash balances and operating cash flows were generated outside the United States, with management not expecting material adverse liquidity effects from those balances.
Key facts
- Thermo Fisher Scientific Inc.’s total debt was $41.370 billion at September 26, 2026, compared with $39.384 billion at December 31, 2025. source
- Thermo Fisher Scientific Inc.’s cash and cash equivalents were $5.461 billion at September 26, 2026, compared with $9.852 billion at December 31, 2025. source
- Thermo Fisher Scientific Inc.’s short-term obligations and current maturities of long-term obligations totaled $2.26 billion as of September 26, 2026. source
- Thermo Fisher Scientific Inc.’s net cash used in investing activities was $8.874 billion in the first nine months of 2026, compared with $4.938 billion in the first nine months of 2025. source
- Thermo Fisher Scientific Inc.’s net cash used in financing activities was $1.541 billion in the first nine months of 2026, compared with $1.725 billion in the first nine months of 2025. source
- In the first nine months of 2026, Thermo Fisher Scientific Inc. received $5.24 billion from debt issuance and used $2.52 billion to repay debt. source
- In the first nine months of 2025, Thermo Fisher Scientific Inc. received $3.34 billion from debt issuance and net commercial paper activity and used $1.63 billion to repay debt. source
- Thermo Fisher Scientific Inc.’s revolving credit facility provides up to $5.00 billion of unsecured, multicurrency revolving credit. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | negative | realized | -3.8% | Thermo Fisher Scientific Inc.’s cash and cash equivalents were $5.461 billion at September 26, 2026, compared with $9.852 billion at… |
| cash | negative | realized | -3.5% | Thermo Fisher Scientific Inc.’s net cash used in investing activities was $8.874 billion in the first nine months of 2026, compared with… |
| liability | negative | realized | -1.7% | Thermo Fisher Scientific Inc.’s total debt was $41.370 billion at September 26, 2026, compared with $39.384 billion at December 31, 2025. |
| cash | positive | realized | +0.2% | Thermo Fisher Scientific Inc.’s net cash used in financing activities was $1.541 billion in the first nine months of 2026, compared with… |